Trade

Neuland Laboratories share price

High risk
  • 52%Low risk
  • 52%Moderate risk
  • 52%Balanced risk
  • 52%High risk
  • 52%Extreme risk
  • 11,969.00(2.52%)
    July 9, 2025 15:29:47 PM IST
    • NSE
    • BSE
  • Vol : 168.01K (NSE + BSE)
    Last 20 day avg : 56.36 K

Neuland Laboratories is trading 2.52% upper at Rs 11,969.00 as compared to its last closing price. Neuland Laboratories has been trading in the price range of 12,479.05 & 11,711.65. Neuland Laboratories has given -14.70% in this year & -1.45% in the last 5 days. Neuland Laboratories has TTM P/E ratio 59.54 as compared to the sector P/E of 22.97.There are 2 analysts who have initiated coverage on Neuland Laboratories. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 27.81 Crores in its last quarter.Listed peers of Neuland Laboratories include Pfizer (-0.83%), Astrazeneca Pharma India (1.75%), Neuland Laboratories (2.52%).The Mutual Fund holding in Neuland Laboratories was at 7.43% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Neuland Laboratories was at 22.12% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Key Metrics

Updated on Jul 09, 2025, 11:16 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.10
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    10.10
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    59.19
    Higher than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.37
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.10
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
11,711.65
Highest
12,479.05
52 week range
Lowest
7,575.00
Highest
18,089.55
Neuland Laboratories Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue fell during March quarter by 14.71% from Rs 385.01 crore to Rs 328.36 crore, year-on-year
    • financial-insightsThe company's profit declined by 58.84% year-on-year during the March quarter, dropping from Rs 67.56 crore to Rs 27.81 crore
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Neuland Laboratories Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 12,378.75
  • R2
  • 12,751.35
  • R3
  • 13,152.75
Pivot11,977.35
  • S1
  • 11,604.75
  • S2
  • 11,203.35
  • S3
  • 10,830.75
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Neuland Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Pfizer
Bullish
5,674.00-0.8325,957.2641.476.270.611.60
Astrazeneca Pharma India
Bullish
9,297.001.7523,234.11121.5529.570.263.82
Neuland Laboratories
Bullish
11,969.002.5215,322.5673.849.820.107.17
Unichem Laboratories
Neutral
602.650.594,233.1130.011.68-3.51
Jagsonpal Pharmaceuticals
Bullish
231.150.921,537.7638.936.360.873.18
Neuland Laboratories Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Neuland Laboratories is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holding is moderate at 32.68%
    • InsightsPromoter(s) have decreased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has decreased by 1.74 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 1.14 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    LIC MF Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 3.47
    • % of AUM 4.11
    ITI Pharma and Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 4.38
    • % of AUM 1.98
    PGIM India Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 1.95
    • % of AUM 1.79
    Tata Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 2.43
    • % of AUM 1.78
    Motilal Oswal Nifty MidSmall Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 0.43
    • % of AUM 1.77
    Neuland Laboratories Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-15Audited Results & Final Dividend
    2025-02-10Quarterly Results
    2024-11-06Quarterly Results
    2024-08-01Quarterly Results
    2024-05-10Audited Results & Final Dividend
    About the company Neuland Laboratories
    • IndustryMajor Drugs
    • ISININE794A01010
    • BSE Code524558
    • NSE CodeNEULANDLAB
    Neuland Laboratories Limited is an India-based company. The Company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the pharmaceutical and biotech industry’s chemistry needs. It provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its key molecules include Mirtazapine, an anti-depressant and Levetiracetam, an anti-epileptic agent. The Company’s product portfolio includes over 100 APIs across 10 diverse therapeutic areas.
    • Management Info
    • Davuluri RaoExecutive Chairman of the Board
    • Davuluri RaoChief Executive Officer, Whole Time Vice Chairman of the Board
    • Davuluri RaoWhole Time Vice Chairman of the Board, Joint Managing Director
    • Abhijit MajumdarChief Financial Officer
    • Sharadsrikar KotturiChief Scientific Officer
    • Sarada BhamidipatiCompliance Officer, Company Secretary
    • Ashutosh SinhaChief Quality Officer
    Neuland Laboratories Share Price FAQs

    Neuland Laboratories is trading at 11969.00 as on Wed Jul 09 2025 09:59:47. This is 2.52% upper as compared to its previous closing price of 11674.45.

    The market capitalization of Neuland Laboratories is 15322.56 Cr as on Wed Jul 09 2025 09:59:47.

    The 52 wk high for Neuland Laboratories is 18089.55 whereas the 52 wk low is 7575.00

    Neuland Laboratories can be analyzed on the following key metrics -

    • TTM P/E: 59.54
    • Sector P/E: 22.97
    • Dividend Yield: 0.10%
    • D/E ratio: 0.10

    Neuland Laboratories reported a net profit of 260.11 Cr in 2025.

    The Mutual Fund Shareholding was 7.43% at the end of 31 Mar 2025.